Linking Life Science Data: Design to Implementation, and Beyond

Open PHACTS project closing conference (Vienna, Austria)

Conference: CiMUS Innopharma Open Innovation Day

On February 18, 2015, Posted by , In Conferences, By ,,,, , With Comments Off on Conference: CiMUS Innopharma Open Innovation Day

CiMUS Innopharma Open Innovation Day, Santiago de Compostela, Spain Stefan Senger (GlaxoSmithKline) gave a presentation: What is Open PHACTS and why would you care?

Presentation: What is Open PHACTS and why would you care?

On February 18, 2015, Posted by , In Presentations, By ,,,, , With Comments Off on Presentation: What is Open PHACTS and why would you care?

CiMUS Innopharma Open Innovation Day, Santiago de Compostela, Spain Stefan Senger (GlaxoSmithKline) View presentation

Open PHACTS Phenotypic Screening Workshop

Understanding the knowledge management needs of phenotypic screening (Santiago de Compostela, Spain)

Open PHACTS project extended for another 18 months

On July 22, 2014, Posted by , In News, By ,,, , With Comments Off on Open PHACTS project extended for another 18 months

We are delighted to announce that the Open PHACTS project will be extendedfor 18 months until the end of February 2016. For the extension two new partners – Laboratorios Almirall S.A. and SciBite Limited – will join the consortium and GlaxoSmithKline (GSK) will act as coordinator.

6th Open PHACTS Community Workshop

Open PHACTS for Academia: Using the Open PHACTS Discovery Platform in undergraduate and postgraduate teaching (London, UK)

Press Release: Open PHACTS Foundation announces first three members: GSK, Janssen and Roche

On June 24, 2014, Posted by , In Press Releases, By ,,,, , With Comments Off on Press Release: Open PHACTS Foundation announces first three members: GSK, Janssen and Roche

(PDF) Cambridge, UK – The not-for-profit Open PHACTS Foundation announced its first three members today – GlaxoSmithKline, Janssen and Roche – who will steer the future of the successor organisation to the Innovative Medicines Initiative (IMI)- funded Open PHACTS project. The commitment by these global pharmaceutical industry members signifies a major…

Presentation: Open PHACTS: Data integration for all

On June 10, 2013, Posted by , In Presentations, By ,,, , With Comments Off on Presentation: Open PHACTS: Data integration for all

14th Annual Drug Discovery Summit, Geneva, Switzerland Andrew Leach (GlaxoSmithKline) View presentation

Conference: 14th Annual Drug Discovery Summit

On June 10, 2013, Posted by , In Conferences, By ,,, , With Comments Off on Conference: 14th Annual Drug Discovery Summit

14th Annual Drug Discovery Summit, Geneva, Switzerland Andrew Leach (GlaxoSmithKline) gave a presentation: Open PHACTS: Data integration for all

Conference: Advances and Progress in Drug Design 2013

On February 18, 2013, Posted by , In Conferences, By ,,,,, , With Comments Off on Conference: Advances and Progress in Drug Design 2013

SMi Annual Advances and Progress in Drug Design 2013, London, UK Andrew Leach (GlaxoSmithKline) gave a presentation

Publication: Druggable and biopharmable genome annotation pipeline development

On September 1, 2012, Posted by , In Publications, By ,, , With Comments Off on Publication: Druggable and biopharmable genome annotation pipeline development

The identification of proteins which could be potential targets for new pharmaceutical products is invaluable for the continued improvement people’s quality of life and expansion of available treatment options. In order to aid the discovery of new drug targets, predictions of every human gene likely to be exploitable by compounds…

2nd Open PHACTS Community Workshop

Working with Open PHACTS (London, UK)